ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.

Biolinq Shine’s use of a microsensor array mitigates the need for an introducer needle for sensor placement as in traditional ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device – which is ...

Coca-Cola ( KO -0.66%) and Abbott Laboratories ( ABT -0.43%) are two great examples along those lines. These two companies can offer stability and income to investors, as they belong to the exclusive ...

Le fabricant américain des capteurs de glucose en continu destinés aux diabétiques a lourdement reculé en fin de semaine ...

Glooko plans to develop an end-to-end ‘hospital-to-home’ care support provision for diabetes patients through the resources ...

Insulet PODD has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain. Presently ...

Le géant français du transport maritime et de la logistique CMA CGM a annoncé lundi acquérir le premier opérateur de fret ...

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

L’analyste de UBS, Danielle Antalffy, a défendu l’action, déclarant que les vérifications auprès des médecins, les conversations avec la direction et les enquêtes récentes n’indiquent aucune ...

Le tandem rail-route a de sérieux atouts pour réduire les émissions, sous réserve d’une modernisation du ferroviaire ...

Biolinq announced today that it received FDA de novo clearance for its lead product, the Biolinq Shine wearable biosensor.